Nonacus Galeas Tumor

Genetic testing company Nonacus has launched its comprehensive genomic profiling test Galeas Tumor. The next-generation sequencing assay combines targeted panels covering 519 genes with a linked bioinformatics platform for variant calling. The test joins Nonacus' larger portfolio of clinical cancer tests including Galeas Hereditary Plus and Galeas Bladder.